Prime Medicine, Inc. (PRME)
| Market Cap | 529.21M +138.2% |
| Revenue (ttm) | 4.03M +4.9% |
| Net Income | -198.37M |
| EPS | -1.24 |
| Shares Out | 180.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,114,618 |
| Open | 3.080 |
| Previous Close | 3.130 |
| Day's Range | 2.930 - 3.090 |
| 52-Week Range | 1.110 - 6.940 |
| Beta | 2.36 |
| Analysts | Buy |
| Price Target | 7.56 (+158.02%) |
| Earnings Date | May 7, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $7.56, which is an increase of 158.02% from the latest price.
News
Prime Medicine reports Q1 EPS (28c), consensus (25c)
Reports Q1 revenue $856,000, consensus $844,220. “Prime Medicine (PRME) continues to execute with clear momentum and a focused strategy designed to deliver on the transformative potential of Prime Edi...
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Prime Medicine management to meet with Oppenheimer
Meeting to be held on May 11 hosted by Oppenheimer.
Prime Medicine appoints Makhni as Chief Financial Officer
Prime Medicine (PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer, CFO. Ms. Makhni will oversee Prime Medicine’s financial operations and strategy, including investor relat...
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Oppenheimer bullish on Prime Medicine, initiates with an Outperform
As previously reported, Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target The firm says Prime is a key name to own in the…
Prime Medicine initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Prime Medicine (PRME) with an Outperform rating and $11 price target
Prime Medicine Transcript: The Citizens Life Sciences Conference 2026
Two in vivo programs are advancing to the clinic with data expected in 2027, while a revived ex vivo program benefits from regulatory flexibility and reduced costs. Prime Editing's DNA-level correction offers broad applicability, strong safety, and competitive advantages in genetic diseases.
Prime Medicine Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing its first in vivo liver-directed clinical programs for Wilson disease and alpha-1 antitrypsin deficiency, with regulatory filings expected soon and initial clinical data anticipated in 2027. Strategic partnerships, a strong IP position, and a cash runway into 2027 support a focused pipeline and ongoing business development.
Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year
Reports FY25 $4.632M vs $2.983M last year. “We are shaping the future of genetic medicine by advancing a platform that is rapidly emerging as the predominant gene editing technology. With…
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM3...
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: 44th Annual J.P. Morgan Healthcare Conference
Prime Editing technology enables precise, safe genome editing with broad disease potential and strong IP protection. Lead programs in Wilson disease and alpha-1 antitrypsin deficiency are advancing toward clinical trials, supported by a $227M cash position and strategic partnerships.
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $6 price target Prime is developing “one-and-done” gene editing therapies centered around indications with sig...
Prime Medicine announces NEJM publication of PM359 data
Prime Medicine (PRME) announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous diseas...
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference
Prime editing is positioned as a safer, more versatile gene editing technology, with a strategic focus on high-value programs like Wilson disease and alpha-1 antitrypsin deficiency. Lead programs are advancing toward clinical trials, with data expected in 2027.
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine transferred with Neutral rating at JPMorgan
JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine (PRME) following a transfer of coverage. The firm says it would consider recommending the shares…
Prime Medicine Transcript: Jefferies London Healthcare Conference 2025
Prime Editing is positioned as a highly versatile and safe gene editing platform, advancing programs in Wilson's disease, AATD, and cystic fibrosis with promising preclinical data and differentiated delivery technology. Key regulatory filings and clinical milestones are expected over the next year.
Prime Medicine Transcript: KOL Event
The event detailed a strategy to address Wilson disease using prime editing, highlighting strong preclinical efficacy, a large addressable market, and a modular platform for rapid expansion. IND/CTA filing is planned for 2026, with initial human data expected in 2027.
Prime Medicine to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine price target lowered to $4.25 from $5 at Citi
Citi analyst Samantha Semenkow lowered the firm’s price target on Prime Medicine (PRME) to $4.25 from $5 and keeps a Neutral rating on the shares.
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as dev...